Trial Profile
A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Korea Otsuka Pharmaceutical
- 01 Jun 2012 Results are to be presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a UCB media release.
- 13 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00993317).
- 07 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (NCT00993317) parent record.